• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, June 30, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Science

Side effects of leukemia drug can be safely reduced by halving dose

Bioengineer by Bioengineer
December 6, 2016
in Science
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Patients with a chronic type of leukaemia could safely reduce the side effects of life-long treatment by cutting their dose in half, according to the results of a University of Liverpool led study presented at an international conference in America this week.

Drugs known as tyrosine kinase inhibitors (TKI) have drastically improved the prognosis for patients with chronic myeloid leukaemia (CML), essentially turning what was a deadly cancer into a chronic disease that can be managed with a daily pill. Although the drugs are highly effective at keeping leukaemia in check, their side effects and cost have led some patients and their doctors to question whether it would be feasible to discontinue their use after a patient achieves consistently negative leukaemia test results.

Under current guidelines, patients who achieve remission with TKI therapy are advised to continue taking the drugs indefinitely, yet it is unclear whether continued therapy is necessary for all patients. Common side effects include chronic headaches, stomach problems, and fatigue, and women are typically advised not to conceive children while taking the drugs due to the high risk of birth defects.

Now, the results of a new study suggest that many CML patients may be able to safely reduce TKI side effects by cutting their dose in half.

In contrast to other trials, which focus on patients who are nearly free of leukaemia as measured by very sensitive tests, the new study included some patients with a stable molecular remission level demarcated according to international standards as MR3 — a level the researchers describe as "good, but not perfect."

Of 174 study participants, the vast majority (93%) showed no evidence of leukaemia rebound one year after cutting their TKI dose, and many reported a significant decrease in TKI-associated side effects within the first three months.

Just 12 participants showed signs of leukaemia recurrence, all of whom regained a remission level of MR3 or better within four months of resuming a full TKI dose.

Participants who started with extremely low levels of leukaemia (MR4) were significantly less likely to experience a leukaemia rebound (seen in 2.4% of these patients) compared with those classified as MR3 (18.4%).

Study lead Professor Richard Clark, from the University's Institute of Translational Medicine, said: "Low rates of rebound overall suggest it is safe for MR3 patients to reduce their TKI dose if desired. Any benefits in terms of reducing side effects should become apparent within the first three months.

"Taken together, these findings indicate that some patients are being unnecessarily over-treated.

"The other important implication is that patients do not have to have extremely low levels of leukaemia on very sensitive tests in order to safely try reducing their TKI dose."

The findings were presented at the American Society of Hematology Annual Meeting, which is taking place in San Diego, California on the 3-6 December.

###

Media Contact

Nicola Frost
[email protected]
@livuninews

http://www.liv.ac.uk

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Senem SEZER won the Altın Kalem Master’s Thesis Award

March 22, 2022

Five or more hours of smartphone usage per day may increase obesity

July 25, 2019

NASA’s terra satellite finds tropical storm 07W’s strength on the side

July 25, 2019

NASA finds one burst of energy in weakening Depression Dalila

July 25, 2019
Please login to join discussion

POPULAR NEWS

  • Pacific whiting

    Oregon State University research finds evidence to suggest Pacific whiting skin has anti-aging properties that prevent wrinkles

    37 shares
    Share 15 Tweet 9
  • University of Miami Rosenstiel School selected for National ‘Reefense’ Initiative focusing on Florida and the Caribbean

    35 shares
    Share 14 Tweet 9
  • Saving the Mekong delta from drowning

    37 shares
    Share 15 Tweet 9
  • Sharks may be closer to the city than you think, new study finds

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

VehiclesUniversity of WashingtonWeaponryZoology/Veterinary ScienceVaccineVaccinesViolence/CriminalsUrogenital SystemVirusVirologyUrbanizationWeather/Storms

Recent Posts

  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers
  • New research: Up to 540,000 lives could be saved worldwide by targeting speed and other main areas
  • Shining some light on the obscure proteome
  • Romantic partners can influence each other’s beliefs and behaviors on climate change, new Yale study finds
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....